Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12A
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
KRAS mutation (239)
KRAS G12C (159)
KRAS G12D (64)
KRAS G12V (36)
KRAS wild-type (26)
KRAS G13D (22)
KRAS G12R (18)
RAS wild-type (17)
KRAS G12 (10)
KRAS G12S (9)
KRAS G13 (8)
KRAS mutation + STK11 mutation (8)
KRAS Q61H (7)
KRAS exon 2 mutation (7)
TP53 mutation + KRAS mutation (6)
KRAS G12C + STK11 mutation (5)
EGFR mutation + KRAS mutation (4)
KRAS A146 (4)
KRAS A59T (4)
KRAS Q61 (4)
KRAS A146T (3)
KRAS G12C + TP53 mutation (3)
KRAS G12D + STK11 mutation (3)
KRAS Y96D (3)
KRAS Y96S (3)
EGFR T790M + KRAS mutation (2)
EGFR V802I + KRAS mutation (2)
KEAP1 mutation + KRAS mutation (2)
KRAS A146V (2)
KRAS A59 (2)
KRAS A59S (2)
KRAS G12C + KEAP1 mutation (2)
KRAS G12D + KRAS G12V (2)
KRAS G13A (2)
KRAS G13C (2)
KRAS G13D + BRAF mutation (2)
KRAS K117 (2)
KRAS Q99L (2)
KRAS R68M (2)
KRAS exon 12 mutation (2)
KRAS exon 2 wild-type (2)
KRAS exon 3 mutation (2)
KRAS exon 4 mutation (2)
KRAS mutation + EGFR wild-type (2)
KRAS mutation + STK11 mutation + KEAP1 mutation (2)
KRAS mutation + TP53 wild-type (2)
PIK3CA mutation + KRAS mutation (2)
STK11 mutation + KEAP1 mutation + KRAS G12C (2)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + KRAS mutation (1)
APC mutation + KRAS mutation (1)
ARID1A mutation+ KRAS G12C (1)
BRAF V600E + KRAS G12R (1)
DICER1 A1690Gfs*9 + DICER1 E1813Q + KRAS G12L (1)
EGFR T790M + KRAS G12V (1)
KIR2DS4 mutation + KRAS mutation (1)
KRAS G12A + BRAF D549N (1)
KRAS G12C + ATM wild-type (1)
KRAS G12C + KRAS G12V (1)
KRAS G12C + SMARCA4 wild-type (1)
KRAS G12D + DNMT3A C559fsX (1)
KRAS G12V + BRAF V600E (1)
KRAS G12V + STK11 mutation (1)
KRAS G12V + TP53 mutation + APC mutation (1)
KRAS G60D (1)
KRAS G61 (1)
KRAS G61H + KRAS G12A (1)
KRAS N116H (1)
KRAS N116T (1)
KRAS Q22X (1)
KRAS Q61K (1)
KRAS Q61L (1)
KRAS S89P (1)
KRAS V12 (1)
KRAS codon 12 mutation + KRAS codon 13 mutation + EGFR mutation (1)
KRAS exon 13 mutation (1)
KRAS mutation + ATM mutation (1)
KRAS mutation + KEAP1 mutation (1)
KRAS mutation + SMARCA4 mutation (1)
KRAS mutation + STK11 deletion + KEAP1 deletion (1)
KRAS mutation + STK11 mutation + TP53 mutation (1)
KRAS mutation + U2AF1 mutation (1)
KRAS mutation + KMT2C mutation (1)
MAP2K1 G128D + KRAS mutation (1)
MET exon 14 mutation + KRAS G12A (1)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PIK3CA mutation + PTEN mutation + KRAS mutation (1)
PIK3CA wild-type + KRAS wild-type (1)
PTPN11 mutation + KRAS wild-type (1)
STK11 mutation + KEAP1 mutation + KRAS wild-type (1)
BRAF V600E + KRAS G12D (0)
CDKN2A mutation + CDKN2B mutation + KRAS mutation (0)
CDKN2A mutation + KRAS mutation (0)
KRAS A146P (0)
KRAS A59 (0)
KRAS G61H (0)
KRAS mutation + TP53 mutation (0)
KRAS mutation (239)
KRAS G12C (159)
KRAS G12D (64)
KRAS G12V (36)
KRAS wild-type (26)
KRAS G13D (22)
KRAS G12R (18)
RAS wild-type (17)
KRAS G12 (10)
KRAS G12S (9)
KRAS G13 (8)
KRAS mutation + STK11 mutation (8)
KRAS Q61H (7)
KRAS exon 2 mutation (7)
TP53 mutation + KRAS mutation (6)
KRAS G12C + STK11 mutation (5)
EGFR mutation + KRAS mutation (4)
KRAS A146 (4)
KRAS A59T (4)
KRAS Q61 (4)
KRAS A146T (3)
KRAS G12C + TP53 mutation (3)
KRAS G12D + STK11 mutation (3)
KRAS Y96D (3)
KRAS Y96S (3)
EGFR T790M + KRAS mutation (2)
EGFR V802I + KRAS mutation (2)
KEAP1 mutation + KRAS mutation (2)
KRAS A146V (2)
KRAS A59 (2)
KRAS A59S (2)
KRAS G12C + KEAP1 mutation (2)
KRAS G12D + KRAS G12V (2)
KRAS G13A (2)
KRAS G13C (2)
KRAS G13D + BRAF mutation (2)
KRAS K117 (2)
KRAS Q99L (2)
KRAS R68M (2)
KRAS exon 12 mutation (2)
KRAS exon 2 wild-type (2)
KRAS exon 3 mutation (2)
KRAS exon 4 mutation (2)
KRAS mutation + EGFR wild-type (2)
KRAS mutation + STK11 mutation + KEAP1 mutation (2)
KRAS mutation + TP53 wild-type (2)
PIK3CA mutation + KRAS mutation (2)
STK11 mutation + KEAP1 mutation + KRAS G12C (2)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + KRAS mutation (1)
APC mutation + KRAS mutation (1)
ARID1A mutation+ KRAS G12C (1)
BRAF V600E + KRAS G12R (1)
DICER1 A1690Gfs*9 + DICER1 E1813Q + KRAS G12L (1)
EGFR T790M + KRAS G12V (1)
KIR2DS4 mutation + KRAS mutation (1)
KRAS G12A + BRAF D549N (1)
KRAS G12C + ATM wild-type (1)
KRAS G12C + KRAS G12V (1)
KRAS G12C + SMARCA4 wild-type (1)
KRAS G12D + DNMT3A C559fsX (1)
KRAS G12V + BRAF V600E (1)
KRAS G12V + STK11 mutation (1)
KRAS G12V + TP53 mutation + APC mutation (1)
KRAS G60D (1)
KRAS G61 (1)
KRAS G61H + KRAS G12A (1)
KRAS N116H (1)
KRAS N116T (1)
KRAS Q22X (1)
KRAS Q61K (1)
KRAS Q61L (1)
KRAS S89P (1)
KRAS V12 (1)
KRAS codon 12 mutation + KRAS codon 13 mutation + EGFR mutation (1)
KRAS exon 13 mutation (1)
KRAS mutation + ATM mutation (1)
KRAS mutation + KEAP1 mutation (1)
KRAS mutation + SMARCA4 mutation (1)
KRAS mutation + STK11 deletion + KEAP1 deletion (1)
KRAS mutation + STK11 mutation + TP53 mutation (1)
KRAS mutation + U2AF1 mutation (1)
KRAS mutation + KMT2C mutation (1)
MAP2K1 G128D + KRAS mutation (1)
MET exon 14 mutation + KRAS G12A (1)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PIK3CA mutation + PTEN mutation + KRAS mutation (1)
PIK3CA wild-type + KRAS wild-type (1)
PTPN11 mutation + KRAS wild-type (1)
STK11 mutation + KEAP1 mutation + KRAS wild-type (1)
BRAF V600E + KRAS G12D (0)
CDKN2A mutation + CDKN2B mutation + KRAS mutation (0)
CDKN2A mutation + KRAS mutation (0)
KRAS A146P (0)
KRAS A59 (0)
KRAS G61H (0)
KRAS mutation + TP53 mutation (0)
›
Related tests:
therascreen® KRAS RGQ PCR Kit (5)
therascreen® KRAS RGQ PCR Kit (5)
Associations
(14)
News
Trials
Search handles
@HHorinouchi
@StephenVLiu
@cczielinski
@pashtoonkasi
Search handles
@HHorinouchi
@StephenVLiu
@cczielinski
@pashtoonkasi
Filter by
Latest
11ms
BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12A • KRAS G12 • KRAS G13 • KRAS Q61H • KRAS A146V • KRAS G13C
|
BI-2493
12ms
The Frequency of Specific #KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer. 🇪🇸 🇪🇺 G12A incidence, though! @manjuggm @fireflyann @afm1003 @udai_banerji https://t.co/WE7F1kImFv (@CrozrX)
12 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12A
1year
A 12-11 One more trial!! Pan #RAS G12i Ph I/Ib 📌https://t.co/xNGnaEYbli 📌n=141 📌RMC6326 📌For KRAS G12A/G12D/ G12R/ G12S or G12V mutant #CRC & other solid tumors 📌Primary end points: DLT, Safety 📌Trial open in the US https://t.co/2y2vpJDmAH #CRCTrialsChat #CRCSM (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S
2years
Any ideas what to offer to a patient with NSCLC with KRAS G12A mutation which has progressed on all kinds of immune and chemotherapy? (@cczielinski)
2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12A • KRAS G12
2years
#TTLC22 P14 by Dr. @JessBoyceMD characterizes patients with NSCLC and soft tissue metastases (skin, muscle). Majority had #KRAS mutations (esp G12A) and that has definitely been my own experience. Curious about what is driving the tropism here. (@StephenVLiu)
2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12A • KRAS G12
almost3years
As you can see in this #ovariancancer #LGSOC presentation, response across multiple #KRAS variants and WT, among them G12A top right corner. Not aware of that specific mutation response in other cancers for this comprehensive #MAPK #FAKi #KRAS platform. (@CrozrX)
almost 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12A • KRAS G12
3years
🙌🏾 to open at @IntMedatIowa few days. While #pancreascancer #PANCSM is the major cohort, the vaccine 💉 is for multiple KRAS mutations. So #lcsm #HPBCSM #cholangiocarcinoma #CRCSM and I believe #ovariancancer. Using the #ctDNA @NateraOncology. G12D G12R G12V G12A G12C G12S G13D (@pashtoonkasi)
3 years ago
Circulating tumor DNA
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12S
over3years
#KRAS #lungcancer variants G12V G12D G12A WT @IASLC @LungCancerEu @GO2Foundation @ALKLungCancer @lcrf_org @LUNGevity Dr. Ross Camidge discusses launch of #RAMP202 Vs-6766 /Defactinib registrational clinical study (RAF/MEKi -FAKi) @dave6408 @SarahCannonDocs https://t.co/U33fPMonYL (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over3years
I'll dare to put in little diversity in here! ☺#wizard @udai_banerji accomplishment in a fantastic RAF •MEKi efficacy, DOR and safety profile in KRAS •G12V •G12D •G12A •WT variants! Amazing breakthrough in #LGSOC #NSCLC #PancreaticCancer #CRC #LessIsMore #IntermittentDosing (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
over3years
Promising multiple KRAS variants platform in dual RAF •MEK inhibitor VS-6766 (RO5126766) FAKi •Defactinib. G12V G12D G12A WT, giant leap in KRAS development! Efficacy, durability, safety profile! @udai_banerji is a wizard! @JackWestMD #NSCLC #PDAC #CRC #LGSOC (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over3years
Not just G12C, but G12V •G12D •WT •G12A KRAS variants #NSCLC #LGSOC #PancreaticCancer #PDAC #CRC Vs-6766 /Defactinib https://t.co/KpdKLDWdLq (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over3years
It's not only G12C with KRAS breakthrough data, but also G12D G12V G12A WT.. which bears major implications for pancreatic cancer, CRC, MM.. Also, synergistic combo with AMG510 in KRAS G12C. Phenomenal 65% ORR, 4% TEAE! Expanding cohorts.. https://t.co/VDN8PpGNsm (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
Lumakras (sotorasib)
over3years
65% ORR, 4% TEAE across G12D G12V WT G12A.. KRAS variants. LGSOC cohort expansion to pancreatic cancer, CRC, NSCLC. Also great synergy with AMG510 KRAS G12C. https://t.co/VDN8PpYoQW (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
Lumakras (sotorasib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login